T-DM1 Provides Better Breast Cancer Progression-Free Survival Than Just Herceptin And

[News]

T-DMI, a combination of trastuzumab (Herceptin) and a cell-killing agent developed by ImmunoGen, has demonstrated superior progression-free survival when compared to just Herceptin and chemotherapy. A Phase II trial with 137 patients with HER2-positive metastatic breast cancer focused on T-DMI as the initial breast cancer treatment...

More... (http://www.medicalnewstoday.com/articles/221862.php)